Waltham, Mass.-based Fractyl Laboratories has scooped up CE marking for its Revita DMR system for minimally invasive duodenal mucosal resurfacing for treating metabolic diseases.
The approval was based on data, which showed the system improved metabolic control in patients with Type 2 diabetes and fatty liver disease. Additionally, it lowered transaminase levels.
The data was presented at the International Liver Conference of the European Association in Barcelona, Spain. — Anisa Jibrell